Trial of clofibrate.
作者信息
Dewar H A, Oliver M F
出版信息
Br Med J. 1972 Feb 19;1(5798):506. doi: 10.1136/bmj.1.5798.506-a.
Abstract
摘要
相似文献
1
Trial of clofibrate.氯贝丁酯试验。
Br Med J. 1972 Feb 19;1(5798):506. doi: 10.1136/bmj.1.5798.506-a.
2
Clofibrate in coronary heart disease. Effect on morbidity and mortality.
JAMA. 1972 Feb 14;219(7):845-51.
3
Editorial: The value of clofibrate in coronary heart disease.
Am Heart J. 1974 Jan;87(1):1-4. doi: 10.1016/0002-8703(74)90382-2.
4
Trial of clofibrate.氯贝丁酯试验。
Br Med J. 1972 Mar 18;1(5802):750. doi: 10.1136/bmj.1.5802.750-a.
5
6
Five-year trial of clofibrate in ischaemic heart disease.
Br Heart J. 1971 Jan;33(1):145.
7
Clofibrate and niacin in coronary heart disease.氯贝丁酯与烟酸治疗冠心病
JAMA. 1975 Jan 27;231(4):360-81.
8
[Clofibrate and coronary disease].[氯贝丁酯与冠心病]
Duodecim. 1972;88(10):684-7.
9
Present status of clofibrate in Canada.氯贝丁酯在加拿大的现状。
Can Med Assoc J. 1981 Aug 15;125(4):346-8.
10
Influence of treatment adherence in the coronary drug project.
N Engl J Med. 1981 Mar 5;304(10):612-3. doi: 10.1056/NEJM198103053041018.
引用本文的文献
1
All cholesterol-lowering interventions are expected to reduce stroke: Confirmatory data from IMPROVE-IT.所有降胆固醇干预措施预计均可降低中风风险：来自IMPROVE-IT的确证数据。
Data Brief. 2016 Apr 27;7:1541-50. doi: 10.1016/j.dib.2016.04.059. eCollection 2016 Jun.
2
Use of fibrates and cancer risk: a systematic review and meta-analysis of 17 long-term randomized placebo-controlled trials.使用贝特类药物和癌症风险：17 项长期随机安慰剂对照试验的系统评价和荟萃分析。
PLoS One. 2012;7(9):e45259. doi: 10.1371/journal.pone.0045259. Epub 2012 Sep 19.
3
Cholesterol lowering and mortality: the importance of considering initial level of risk.降低胆固醇与死亡率：考虑初始风险水平的重要性。
BMJ. 1993 May 22;306(6889):1367-73. doi: 10.1136/bmj.306.6889.1367.
4
Assessing possible hazards of reducing serum cholesterol.评估降低血清胆固醇的潜在危害。
BMJ. 1994 Feb 5;308(6925):373-9. doi: 10.1136/bmj.308.6925.373.
Zotero 插件